Valuation: Bould Opportunities PLC

Market Cap 5.71K 5.12K 4.68K 4.27K 8.05K 536K 8.3K 56.39K 22.48K 286K 21.42K 20.96K 904K P/E 2019
-0.01x
P/E 2020 -0.02x
Enterprise Value -78.29K -70.22K -64.18K -58.58K -110K -7.36M -114K -774K -308K -3.93M -294K -288K -12.4M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
65.12%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Director of Finance/CFO 65 13/05/2021
Chief Tech/Sci/R&D Officer 61 01/01/2025
Director TitleAgeSince
Director/Board Member 45 28/01/2019
Chairman 70 20/05/2019
Director/Board Member 61 13/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+24.32% - - 3.54M
-1.79%+0.38%+10.87%+60.47% 45.58B
-0.46%+9.16%-8.31%+38.95% 40.87B
-1.83%+0.94%-6.90%+25.84% 23.46B
+1.87%+0.32%+48.09%+44.82% 18.82B
-0.81%+2.81%+33.51%+51.74% 16.16B
-0.57%+0.52%+19.49%+41.16% 14.61B
-2.88%+3.31%-29.34%-58.56% 12.08B
+0.35%-9.22%-16.13%+9.95% 9.25B
+0.29%+2.41%-9.05%+92.83% 9.54B
Average -0.61%+4.78%+4.69%+34.13% 19.04B
Weighted average by Cap. -0.85%+4.08%+5.97%+39.43%

Financials

2019 2020
Net sales - -
Net income -832K -746K -682K -623K -1.17M -78.21M -1.21M -8.22M -3.28M -41.73M -3.12M -3.06M -132M -306K -274K -251K -229K -431K -28.76M -445K -3.02M -1.21M -15.35M -1.15M -1.12M -48.45M
Net Debt -378K -339K -310K -283K -533K -35.53M -550K -3.73M -1.49M -18.96M -1.42M -1.39M -59.85M -84K -75.34K -68.85K -62.85K -118K -7.9M -122K -830K -331K -4.21M -315K -309K -13.3M
Logo Bould Opportunities PLC
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Employees
-